ArticleJournal of neurology2022
PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice.
Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.Journal of neurology · 2023Pooled it
- A first in disease trial of the safety, tolerability, and anti-seizure effects of ES-481 in drug-resistant epilepsy.Epilepsia open · 2026Trial
- Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study.Journal of neurology · 2024Trial
- Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.Epilepsia open · 2024Trial
- Bistromathics in Epilepsy and the Relativity of Numbers.CNS drugs · 2026Article
- DECREASE study: A European pool-analysis of patients with significant reductions in concomitant antiseizure medications in cenobamate Early Access Programs.Epilepsia open · 2026Article
- Efficacy and Safety of Adjunctive Perampanel in Young Children (7-46 Months) With Drug-Resistant Epilepsy: A Real-World Study.CNS neuroscience & therapeutics · 2026Article
- Efficacy and safety of perampanel as first adjunctive therapy in patients with focal-onset seizures or generalized tonic-clonic seizures in four post-marketing studies across regions.Epilepsia open · 2026Article
- Emptying the fridge syndrome: a case of nocturnal food craving associated with peak perampanel concentration.Epilepsy & behavior reports · 2025Article
- Effectiveness of perampanel as the only adjunctive anti-seizure medication in adults: Final results from the observational PERPRISE study in Germany.Epilepsia open · 2025Observational
- Perampanel, Brivaracetam, Cenobamate, Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: A Comprehensive Narrative Review.Journal of clinical medicine · 2025Review
- Real-world use of adjunctive perampanel for focal-onset seizures in Italy: A mirroring clinical practice study of perampanel in adults and adolescents (AMPA).Epilepsia open · 2025Observational
- Effectiveness and safety of perampanel for pediatric patients with epilepsy: A real-world study from China.Pediatric investigation · 2025Article
- Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe.Neurology and therapy · 2025Article
- Review
- Effectiveness and safety of Perampanel in refractory status epilepticus: a case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Clinical factors associated with perampanel retention, response, seizure freedom and tolerability: real-world evidence from the PERMIT Extension study.Therapeutic advances in neurological disorders · 2025Article
- Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term.Scientific reports · 2024Article
- Efficacy and safety of add-on antiseizure medications for focal epilepsy: A network meta-analysis.Epilepsia open · 2024Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 12 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) study was a pooled analysis of data from 44 real-world studies from 17 countries, in which people with epilepsy (PWE; focal and generalized) were treated with perampanel (PER). Retention and effectiveness were assessed after 3, 6, and 12 months, and at the last visit (last observation carried forward). Effectiveness assessments included 50% responder rate (≥ 50% reduction in seizure frequency from baseline) and seizure freedom rate (no seizures since at least the prior visit); in PWE with status epilepticus, response was defined as seizures under control. Safety and tolerability were assessed by evaluating adverse events (AEs) and discontinuation due to AEs. The Full Analysis Set included 5193 PWE. Retention, effectiveness and safety/tolerability were assessed in 4721, 4392 and 4617, respectively. Retention on PER treatment at 3, 6, and 12 months was 90.5%, 79.8%, and 64.2%, respectively. Mean retention time on PER treatment was 10.8 months. The 50% responder rate was 58.3% at 12 months and 50.0% at the last visit, and the corresponding seizure freedom rates were 23.2% and 20.5%, respectively; 52.7% of PWE with status epilepticus responded to PER treatment. Overall, 49.9% of PWE reported AEs and the most frequently reported AEs (≥ 5% of PWE) were dizziness/vertigo (15.2%), somnolence (10.6%), irritability (8.4%), and behavioral disorders (5.4%). At 12 months, 17.6% of PWEs had discontinued due to AEs. PERMIT demonstrated that PER is effective and generally well tolerated when used to treat people with focal and/or generalized epilepsy in everyday clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.